{
    "root": "91300721-f64e-447d-9693-43bdd03509d8",
    "code": "34391-3",
    "codeSystem": "2.16.840.1.113883.6.1",
    "displayName": "Human Prescription Drug Label",
    "name": {
        "text": "Lamotrigine"
    },
    "value": "20240507",
    "ingredients": [
        {
            "name": "LAMOTRIGINE",
            "code": "U3H27498KS"
        },
        {
            "name": "CROSCARMELLOSE SODIUM",
            "code": "M28OL1HH48"
        },
        {
            "name": "MICROCRYSTALLINE CELLULOSE",
            "code": "OP1R32D61U"
        },
        {
            "name": "MAGNESIUM STEARATE",
            "code": "70097M6I30"
        },
        {
            "name": "MANNITOL",
            "code": "3OWL53L36A"
        },
        {
            "name": "SILICON DIOXIDE",
            "code": "ETJ7Z6XBU4"
        },
        {
            "name": "STARCH, CORN",
            "code": "O8232NY3SJ"
        },
        {
            "name": "SUCRALOSE",
            "code": "96K6UQ3ZD4"
        },
        {
            "name": "MALTODEXTRIN",
            "code": "7CVR7L4A2D"
        },
        {
            "name": "MODIFIED CORN STARCH (1-OCTENYL SUCCINIC ANHYDRIDE)",
            "code": "461P5CJN6T"
        }
    ],
    "indications": "Lamotrigine orally disintegrating tablets are indicated for: Epilepsy—adjunctive therapy in patients aged 2 years and older: partial-onset seizures. primary generalized tonic-clonic seizures. generalized seizures of Lennox-Gastaut syndrome. ( 1.1 ) Epilepsy—monotherapy in patients aged 16 years and older: Conversion to monotherapy in patients with partial-onset seizures who are receiving treatment with carbamazepine, phenytoin, phenobarbital, primidone, or valproate as the single antiepileptic drug. ( 1.1 ) Bipolar disorder: Maintenance treatment of bipolar I disorder to delay the time to occurrence of mood episodes in patients treated for acute mood episodes with standard therapy. ( 1.2 ) Limitations of Use: Treatment of acute manic or mixed episodes is not recommended. Effectiveness of lamotrigine orally disintegrating tablets in the acute treatment of mood episodes has not been established.",
    "contraindications": "Dosing is based on concomitant medications, indication, and patient age. ( 2.1 , 2.2 , 2.3 , 2.4 ) To avoid an increased risk of rash, the recommended initial dose and subsequent dose escalations should not be exceeded. ( 2.1 ) Do not restart lamotrigine orally disintegrating tablets in patients who discontinued due to rash unless the potential benefits clearly outweigh the risks. ( 2.1 , 5.1 ) Adjustments to maintenance doses will be necessary in most patients starting or stopping estrogen-containing oral contraceptives. ( 2.1 , 5.9 ) Discontinuation: Taper over a period of at least 2 weeks (approximately 50% dose reduction per week). ( 2.1 , 5.10 ) Epilepsy: Adjunctive therapy—See Table 1 for patients older than 12 years and Tables 2 and 3 for patients aged 2 years to 12 years. ( 2.2 ) Conversion to monotherapy—See Table 4. ( 2.3 ) Bipolar disorder : See Tables 5 and 6. ( 2.4 )",
    "warningsAndPrecautions": "Lamotrigine orally disintegrating tablets\n                  \n                  25 mg, white to off-white, round, flat-faced tablets debossed with “L1” on one side and plain on the other supplied in bottles of 30 with child-resistant closure (NDC 27241-183-30). \n                  \n                  50 mg, white to off-white, round, flat-faced tablets debossed with “LT2” on one side and plain on the other supplied in bottles of 30 with child-resistant closure (NDC 27241-184-30).\n                  \n                  100 mg, white to off-white, round, flat-faced tablets debossed with “LT3” on one side and plain on the other supplied in bottles of 30 with child-resistant closure (NDC 27241-185-30).\n                  \n                  200 mg, white to off-white, round, flat-faced tablets debossed with “LT5” on one side and plain on the other supplied in bottles of 30 with child-resistant closure (NDC 27241-186-30).\n                  \n                  Store at 20°C to 25°C (68°F to 77°F); excursions permitted to 15°C to 30°C (59°F to 86°F) [see USP Controlled Room Temperature].",
    "adverseReactions": "Lamotrigine orally disintegrating tablets are contraindicated in patients who have demonstrated hypersensitivity (e.g., rash, angioedema, acute urticaria, extensive pruritus, mucosal ulceration) to the drug or its ingredients [see Boxed Warning, Warnings and Precautions (5.1, 5.3)]."
}